Advancing drug-free treatment for depression

The real brain care starts with networks.

Cortisys is developing autonomous, non-invasive stimulation of brain networks for advancing research and drug-free personalised care of neurological and mental health conditions, starting with depression.

Why networks matter

Brain disorders affect networks, not just isolated brain regions.

Our emotions, thoughts and behaviour emerge from communication between interconnected brain regions.

Depression is associated with changes in activity and connectivity across these networks.

Understanding those connections creates an opportunity to create therapeutic interventions for restoring brain function faster and more effectively.

The unmet need

Too many people endure trial and error when they need effective care.

Depression can make everyday life a struggle and debilitating. Existing treatments help many people, but the need for more effective, accessible care remains.

01 · Treatment
Finding relief can take too much trial and error

Medication often comes first, but finding one that helps can take repeated attempts. When it does not provide sufficient relief, brain stimulation offers an established treatment option.

02 · TMS
A proven approach with room to advance

Transcranial Magnetic Stimulation (TMS) delivers non-invasive electromagnetic pulses to targeted brain regions. Research into brain networks points towards a new opportunity: personalising where, when and how multiple regions are stimulated.

03 · The limitation
The next step requires a new way to stimulate the brain

Cortisys enables fast electronic switching between nearby targets and integrates robotic guidance with the aim of making personalised stimulation easier to deliver to more patients. This technology opens a new paradigm for understanding and caring for the brain.

Cortisys platform

From stimulating single points to orchestrating brain networks.

The Cortisys mTMS system positioned over a seated patient

Designed for brain networks

Cortisys leverages multiple coils to flexibly control the spatial spread of stimulation. For the first time, end points of brain networks can be activated at the speed of neuronal communication, within milliseconds.

Individually tailored protocols

Brain images guide target planning. This connects the protocol to each participant’s anatomy, supporting consistent delivery across sessions with robotic precision.

Automated workflows

The platform is designed to treat depression and other disorders by restoring healthy brain function, with AI-ready, individualized, and autonomous protocols.

Solid foundation

Translating decades of research to market.

  • 5
    Systems deployed
    Finland, Germany, Italy and Brazil in collaboration with key research institutions.
  • 1
    Sale booked in 2026
    First paying customer and strategic partner. System fully commissioned in Q3/2026.
  • 15M+
    Non-dilutive funding
    From the ERC, Novo Nordisk Foundation, Business Finland, and other agencies.
  • 30+
    Scientific publications
    Experimental and technical reports in top peer-reviewed journals. Leading neuroscientific discoveries.

Latest frontier in neuroscience

If we know depression is a network condition, why is everyone treating one spot?

Depression involves several brain networks at once :: cognitive control, default mode, reward and affective. Traditional TMS can only reach one node at a time. Cortisys mTMS covers the network.

The Cortisys team reviewing tractography in the navigation software
Photo: Mikko Raskinen / Aalto University. Read the article by Aalto University.
What is the core technology behind Cortisys?
Cortisys stimulates the brain non-invasively with a stack of coils in one assembly. This technology is known as multi-locus TMS (mTMS), and enables the stimulus in the brain to be steered electronically without the coils being repositioned manually.
Is it safe?
TMS is non-invasive, drug-free and well-tolerated, being approved by the FDA for depression treatment since 2008 and incorporated into the healthcare system in many countries, such as Finland, Germany, Canada, and Australia. The Cortisys platform builds on decades of TMS research at Aalto University, Finland, and its international partner institutions, with 30+ technical and experimental publications in top journals behind it.
Why a network, not a spot?
Most neurological and psychiatric disorders emerge from malfunctions in networks connecting multiple brain areas. Conventional TMS stimulates a single, isolated area at a time, having a limited impact on the brain's orchestrated interactions. Cortisys multi-stimulator technology is the first to enable multi-site stimulation, precisely designed to treat depression and other disorders as network conditions. This new therapeutic approach is expected to provide meaningful relief to patients, unlocking the full potential of neuromodulation against depression.
Where is the platform today?
Five systems have been deployed to research sites in Finland (Aalto University), Germany (University of Tübingen), Italy (University of Chieti-Pescara) and Brazil (University of São Paulo), and the company has delivered its first system to a paying customer in Finland (University of Jyväskylä).

Team

The people who invented the tech, now building the company.

Founded in 2025 out of Aalto University (Finland) from decades of dedicated research with its international partner institutions.

  • Dr. Dubravko Kicic
    Dubravko Kicic, PhD
    Founder · CEO

    MBA. Ex-CEO BIOCentre, Ex-CEO Institute of Imunology (Croatia), and Ex-Elekta Neuroscience. 15+ years in the MedTech industry, 20+ years in NeuroTech.

  • Victor Souza, PhD
    Victor Souza, PhD
    Founder · CTO

    15+ years in NeuroTech. Led R&D teams from concept to deploy. Expert in neurostimulation and neuroimaging. 4 years admin in Google SoC.

  • Prof. Risto Ilmoniemi
    Prof. Risto Ilmoniemi, PhD
    Founder · Chief Scientific Officer

    Key opinion leader with 30+ years in NeuroTech. Founder and ex-CEO of Nexstim Plc. Inventor of TMS–EEG and multi-locus TMS. Raised €25M+ in research funding.

  • Dr. Heikki Sinisalo
    Heikki Sinisalo, PhD
    Technical Co-founder

    15+ years in industry and 7+ years in NeuroTech. Expert in power electronics. Designer of the multi-locus TMS electronics, deployed in 4 countries.

Backed and hosted by

SOSV/HAX, Nexstim, and the universities that run the platform.

  • SOSV / HAX
  • Nexstim
  • Aalto University School of Science
  • University of Chieti-Pescara
  • Eberhard Karls Universität Tübingen
  • University of São Paulo

In the news

From the research that became Cortisys.

Contact

Clinics, research sites, investors — talk to the founders.

AddressA Grid, Otakaari 5
02150 Espoo, Finland
We reply from contact@cortisys.fi.